Table 5 Published studies of stereotactic radiation therapy for hepatic lesions
Study | No. of lesions | No. of patients | Total dose (Gy) | No. of fractions | Lesion volume/Lesion size (medians) | Post-treatment period median in months | Local control at 1 and 2 years | Comments |
|---|---|---|---|---|---|---|---|---|
Blomgren et al. 1998[20] | HCC and CC (n = 20) | 41 | 30 | 2-3 | 22 cc/- | 11 | 100% overall control | Retrospective |
HM (n = 21) | 24 cc/- | 95% overall control | ||||||
Herfarth et al. 2001[13] | HCC + CC (n = 4) | 37 | 14-26 | 1 | 10 cc/- | - | 67/- | Phase I/II |
HM (n = 56) | ||||||||
Fuss et al. 2004[21] | HCC (n = 1) | 15 | 36 | 3-6 | 56 cc/- | 6.5 | 94/- | Retrospective |
HM (n = 17) | ||||||||
Schefter et al. 2005 (27) | HM (n = 18) | 18 | 36-60 | 3 | 18 cc/- | - | - | Phase I |
Body Frame | ||||||||
Mendez et al. 2006[22] | HCC (n = 11) | 25 | 25–37.5 | 3-5 | 22 cc/32 mm | 12.9 (1.1–322) | 94/82 | Phase I/II |
Body Frame | ||||||||
75/75 (HCC) | ||||||||
HM (n = 34) | 100/86 | |||||||
(HM) | ||||||||
Wulf et al. 2006[6] | HCC + CC (n = 5) | 44 | 21-36 | 1-3 | - | 15 | 92/66 | Phase I |
Body Frame | ||||||||
HM (n = 39) | ||||||||
Hoyer et al. 2006[23] | HM CRC (n = 44) | 64 | 45 | 3 | -/35 | 4.5 years | -/79 | Phase II |
Body Frame | ||||||||
Kavanagh et al. 2006[24] | HM (n = 36) | 36 | 60 | 3 | 14 cc/6 | 19 | 93% at 18 months | Phase I/II |
Body Frame | ||||||||
Katz et al. 2007[25] | HM (n = 174) | 69 | 30-55 | 7-20 | 9.9 cc/27 mm | 14.5 | 76/57 | Retrospective |
Exac Trac | ||||||||
Tse et al. 2008[26] | HCC + CC (n = 31 + 10) | 41 | 24–54 | 6 | 173 cc | 17.6 (10.8 – 39.2) | 65% | Phase I |
Respiration control | ||||||||
Choi et al. 2008[7] | HCC (n = 32. including 9 PT) | 31 | 30 – 39 | 3 | 25 cc/- | 10.5 (2 – 18.5) | 71.9% at the median of 10.5 months | Retrospective |
CyberKnife | ||||||||
Rusthoven et al. 2009[15] | HM (n = 63) | 47 | 60 | 3 | 15 cc/27 mm | 16 | 95/92 | Phase I/II |
Lee et al. 2009[27] | HM (n = 68) | 68 | 27-60 | 6 | 75.2 cc/- | 10.8 | 71/- | Phase I |
Respiration control | ||||||||
Ambrosino et al. 2009[1] | HM (n = 27) | 27 | 25-60 | 3 | 69 cc/- | 13 (6–16) | 85.2% overall control | Retrospective |
CyberKnife | ||||||||
Goodman et al. 2009[3] | HCC + CC (n = 7) | 26 | 18-30 | 1 | 33 cc/- | 17.3 (2–55) | 77/- | Phase I |
CyberKnife | ||||||||
HM (n = 19) | ||||||||
Van der Pool et al. 2010[4] | HM CRC (n = 31) | 20 | 37.5 | 3 | -/23 mm | 26 (6–57) | -/74 | Retrospective |
Body Frame | ||||||||
Cardenes et al. 2010[28] | HCC (n = 25. including 3 PT) | 17 | 36-48 | 3 | 34 cc/40 mm | 24 (10–42) | 100% | Phase I |
CyberKnife | ||||||||
Present study 2010 | 153 | 120 | 27-45 | 2-4 | 73 cc/48 mm | 15 (12–18) | 80.4/72.5 | Retrospective |
CyberKnife | ||||||||
HCC (n = 48. including 3 PT) | 42 | 27-45 | 2-3 | 87 cc/48 mm | 13.7 | 90.5/90.5 | ||
73.3/67.4 | ||||||||
HM (n = 99) | 72 | 30-45 | 3-4 | 54 cc/47 mm | 15.5 | 100/- | ||
CC (n = 6) | 6 | 39-45 | 3-4 | 208 cc/65 mm | 11 |